2013

Venugopal, B. et al. (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research, 19 (15). pp. 4262-4272. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-13-0312)

Steele, C.W., Jamieson, N.B., Evans, T.R.J., McKay, C.J., Sansom, O.J., Morton, J., and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108 (5). pp. 997-1003. ISSN 0007-0920 (doi:10.1038/bjc.2013.24)

Macpherson, I.R., Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A., and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49 (4). pp. 782-789. ISSN 0959-8049 (doi:10.1016/j.ejca.2012.09.036)

Karim, S.A., Creedon, H., Patel, H., Carragher, N.O., Morton, J.P., Muller, W.J., Evans, T.R.J., Gusterson, B., Sansom, O.J., and Brunton, V.G. (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology . ISSN 0022-3417 (doi:10.1002/path.4202) (In Press)

Lassen, U. et al. (2013) Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy and Pharmacology, 71 (2). pp. 543-549. ISSN 0344-5704 (doi:10.1007/s00280-012-2038-0)

Nobis, M. et al. (2013) Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of Src in pancreatic cancer. Cancer Research, 73 (15). pp. 4674-4686. ISSN 0008-5472 (doi:10.1158/0008-5472.CAN-12-4545)

Poplin, E. et al. (2013) Randomized, multicenter, phase 2 study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. Journal of Clinical Oncology . ISSN 0732-183X (In Press)

2012

Cairney, C.J., Bilsland, A.E., Evans, T.R.J., Roffey, J., Bennett, D.C., Narita, M., Torrance, C., and Keith, W.N. (2012) Cancer cell senescence: a new frontier in drug development. Drug Discovery Today, 17 (5-6). pp. 269-276. ISSN 1359-6446 (doi:10.1016/j.drudis.2012.01.019)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12 (536). ISSN 1471-2407 (doi:10.1186/1471-2407-12-536)

Jamieson, N.B., Morran, D.C., Morton, J.P., Ali, A., Dickson, E.J., Carter, C.R., Sansom, O.J., Evans, T.R., McKay, C.J., and Oien, K.A. (2012) MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 18 (2). pp. 534-545. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-11-0679)

Olmos, D. et al. (2012) Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. Journal of Clinical Oncology, 30 (9). pp. 996-1004. ISSN 0732-183X (doi:10.1200/JCO.2010.34.5074)

2011

Venugopal, B., and Evans, T.R.J. (2011) Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry, 18 (11). pp. 1658-1671. ISSN 0929-8673

Lolkema, M. P. et al. (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clinical Cancer Research, 17 (3). pp. 581-588. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-10-2159)

Boss, D.S., Glen, H., Beijnen, J.H., de Jong, D., Wanders, J., Evans, T.R.J., and Schellens, J. H.M (2011) Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori, 97 (1). pp. 109-14. ISSN 0300-8916

Leijen, S., Soetekouw, P.M.M.B., Evans, T.R.J., Nicolson, M., Schellens, J.H.M., Learoyd, M., Grinsted, L., Zazulina, V., Pwint, T., and Middleton, M. (2011) A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68 (6). pp. 1619-1628. ISSN 0344-5704 (doi:10.1007/s00280-011-1732-7)

Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S., and Evans, T.R.J. (2011) Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemotherapy and Pharmacology, 67 (6). pp. 1273-1279. ISSN 0344-5704 (doi:10.1007/s00280-010-1419-5)

Venugopal, B., and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36 (6). pp. 427-432. ISSN 0377-8282

2010

Mansi, Janine L. et al. (2010) Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 122 (3). pp. 787-794. ISSN 0167-6806 (doi:10.1007/s10549-010-0989-6)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107 (1). pp. 246-251. ISSN 0027-8424 (doi:10.1073/pnas.0908428107)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139 (2). 586-597.e6. ISSN 0016-5085 (doi:10.1053/j.gastro.2010.04.055)

Morton, JP et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139 (1). pp. 292-303. ISSN 0016-5085 (doi:10.1053/j.gastro.2010.03.034)

2009

Demetri, G.D., Lo Russo , P., Macpherson , I.R., Wang, D., Morgan, J.A., Brunton , V.G., Paliwal, P., Agarwal, S., Voi, M., and Evans, T.R.J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15 (9). pp. 6232-6240. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J., and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009 (1). pp. 1-18. ISSN 1179-1314 (doi:10.2147/BCTT.S6127)

Scott, LC, Evans, TR, Cassidy, J, Harden, S, Paul, J, Ullah, RR, O'Brien, V, and Brown, R (2009) Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. British Journal of Cancer, 101 (3). pp. 410-417. ISSN 0007-0920 (doi:10.1038/sj.bjc.6605175 )

Venugopal, Ba., and Evans, T.R.J. (2009) Coexistent malignant melanoma and renal cell carcinoma. Tumori, 95 (4). pp. 518-520. ISSN 0300-8916

Braidwood, L, Dunn, PD, Hardy, S, Evans, TR, and Brown, SM (2009) Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. Anticancer Research, 29 (6). pp. 2159-2166. ISSN 0250-7005

Graham, J.S., Falk, S., Samuel, L.M., Cendros, J.M., and Evans, T.R.J. (2009) A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy and Pharmacology, 63 (5). pp. 945-952. ISSN 0344-5704 (doi:10.1007/s00280-008-0795-6)

Scott, L et al. (2009) A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 63 (2). pp. 363-370. ISSN 0344-5704 (doi:10.1007/s00280-008-0746-2 )

Koutras, A., Giannopoulou, E., Kritikou, I., Antonacopoulou, A., Evans, T.R.J., Papavassiliou, A.G., and Kalofonos, H. (2009) Antiproliferative effect of exemestane in lung cancer cells. Molecular Cancer, 8 . p. 109. ISSN 1476-4598 (doi:10.1186/1476-4598-8-109)

2008

Roxburgh, P, and Evans, TR (2008) Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy, 25 (11). pp. 1089-1104. ISSN 0741-238X (doi:10.1007/s12325-008-0113-z )

Oien, KA, and Evans, TR (2008) Raising the profile of cancer of unknown primary. Journal of Clinical Oncology, 26 (27). pp. 4373-4375. ISSN 0732-183X (doi:10.1200/JCO.2008.17.6156 )

Sarker, D et al. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clinical Cancer Research, 14 (7). pp. 2075-2081. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-07-1466 )

Jones, RJ, Hawkins, RE, Eatock, MM, Ferry, DR, Eskens, FALM, Wilke, H, and Evans, TR (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61 (3). pp. 435-441. ISSN 0344-5704 (doi:10.1007/s00280-007-0486-8 )

Steele, N. L. et al. (2008) A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors. Clinical Cancer Research, 14 (3). p. 804. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-07-1786)

Holmes, WM, Maclellan, S, Condon, B, Dufes, C, Evans, TR, Uchegbu, IF, and Schatzlein, AG (2008) High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine and Biology, 53 (2). pp. 505-513. ISSN 0031-9155 (doi:10.1088/0031-9155/53/2/015 )

Koutras, AK, Mastronikolis, NS, Evans, TR, Papadeas, ES, Makatsoris, T, and Kalofonos, HP (2008) Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica, 47 (6). pp. 1171-1173. ISSN 0284-186X (doi:10.1080/02841860802213328 )

2007

Guo, X., Evans, T.R.J., Somanath, S., Armesilla, A.L., Darling, J.L., Schatzlein, A., Cassidy, J., and Wang, W. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. British Journal of Cancer, 97 (6). pp. 745-754. ISSN 0007-0920 (doi:10.1038/sj.bjc.6603930)

MacPherson, IRJ, Jones, RJ, and Evans, TR (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007 (1). pp. 9-20. ISSN 1874-0790 (doi:10.2174/1874079000701010009)

Oien, K.A., Dennis, J.L., and Evans, T.R.J. (2007) Metastatic adenocarcinoma of unknown origin. In: Kirkham, N. and Shepherd, N.A. (eds.) Progress in Pathology. Cambridge University Press, Cambridge, UK, pp. 135-162. ISBN 9780521694599

Oien, K.A., Stewart, I., and Evans, T.R.J. (2007) Unknown primary. In: Alison, M. (ed.) Cancer Handbook. John Wiley, Chichester, UK. ISBN 9780470018521

2006

Serrels, A., MacPherson, I.R.J., Evans, T.R.J., Lee, F.Y., Clark, E.A., Sansom, O.J., Ashton, G.H., Frame, M.C., and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5 (12). pp. 3014-3022. ISSN 1535-7163 (doi:10.1158/1535-7163.MCT-06-0382)

Evans, TR (2006) Docetaxel as neoadjuvant therapy in early-stage or locally advanced breast cancer. A view point by T R Jeffry Evans. American Journal of Cancer, 5 (3). pp. 207-208.

Glen, H., and Evans, T.R.J. (2006) Vitamin D analogues as anti-cancer therapies. In: Stolzt, V.D. (ed.) Vitamin D: New Research. Nova Science, New York, USA, pp. 169-179. ISBN 9781600210006

2005

Evans, TR et al. (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An anglo-celtic cooperative oncology group study. Journal of Clinical Oncology, 23 (13). pp. 2988-2995. ISSN 0732-183X (doi:10.1200/JCO.2005.06.156)

Evans, TR (2005) Evaluation of novel agents in pancreatic cancer. Salud I Ciencia, 13 . pp. 10-13.

2004

Jodrell, DI et al. (2004) Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesopliageal adenocarcinoma. European Journal of Cancer, 40 (12). pp. 1872-1877. ISSN 0959-8049 (doi:10.1016/j.ejca.2004.04.032 )

Johnston, SR et al. (2004) A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemotherapy and Pharmacology, 53 (4). pp. 341-348. ISSN 0344-5704 (doi:10.1007/s00280-003-0733-6)

Mackay, HJ, Hoekstra, R, Eskens, F, Loos, WJ, Crawford, D, Voi, M, van Vreckem, A, Evans, TRJ, and Verweij, J (2004) A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clinical Cancer Research, 10 . pp. 2636-2644. ISSN 1078-0432 (doi:10.1158/1078-0432.CCR-03-0327)

White, JD, Marshall, DA, Seywright, MM, and Evans, TR (2004) Primary amyloidosis of the breast associated with invasive breast cancer. Oncology Reports, 11 (4). pp. 761-763. ISSN 1021-335X

Evans, T.R.J., and Keith, W.N. (2004) Intra-Peritoneal Administration of Genetic Therapies: promises and pitfalls. Minerva Ginecologica, 56 (6). pp. 529-538. ISSN 0026-4784

Keith, WN, Bilsland, A, Hardie, M, and Evans, TRJ (2004) Drug Insight: cancer cell immortality - telomerase as a target for novel cancer gene therapies. Nature Clinical Practice Oncology, 1 (2). pp. 88-96. ISSN 1743-4254 (doi:10.1038/ncponc0044)

Scott, LC, and Evans, TR (2004) Novel Cancer Therapeutics: Recent advances and future strategies. National Association of Primary Care Review, Spring . pp. 126-131.

2003

Dalhoff, K et al. (2003) A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. British Journal of Cancer, 89 (2). pp. 252-257. ISSN 0007-0920 (doi:10.1038/sj.bjc.6601104)

White, JD, MacPherson, IRJ, and Evans, TR (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10 (1). pp. 249-251. ISSN 1021-335X

Bilsland, A.E., Anderson, C.J., Fletcher-Monaghan, A.J., McGregor, F., Evans, T.R.J., Ganly, I., Knox, R.J., Plumb, J.A., and Keith, W.N. (2003) Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene, 22 (3). pp. 370-380. ISSN 0950-9232 (doi:10.1038/sj.onc.1206168)

Evans, T.R.J. (2003) Adjuvant systemic therapy. In: Rayter, Z. and Mansi, J. (eds.) Medical Therapy of Breast Cancer. Cambridge University Press, Cambridge, UK, pp. 153-177. ISBN 9780521496322

2002

Cameron, DA et al. (2002) Block sequential adriamycin CMF - optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? British Journal of Cancer, 87 (12). pp. 1365-1369. ISSN 0007-0920 (doi:10.1038/sj.bjc.6600660)

Evans, TRJ, Pentheroudakis, G, Paul, J, McInnes, A, Blackie, R, Raby, N, Morrison, R, Fullarton, GM, Soukop, M, and McDonald, AC (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Annals of Oncology, 13 (9). pp. 1469-1478. ISSN 0923-7534 (doi:10.1093/annonc/mdf243)

Licitra, L, Spinazze, S, Doci, R, Evans, TRJ, Tanum, G, and Ducreux, M (2002) Cancer of the anal region. Critical Reviews in Oncology Hematology, 43 . pp. 77-92. ISSN 1040-8428

Diaz-Rubio, E, Evans, TRJ, Tabernero, J, Cassidy, J, Sastre, J, Eatock, M, Bisset, D, Regueiro, P, and Baselga, J (2002) Capecitabine (Xeloda (R)) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Annals of Oncology, 13 (4). pp. 558-565. ISSN 0923-7534 (doi:10.1093/annonc/mdf065)

Evans, TR, Colston, KW, Lofts, FJ, Cunningham, D, Anthoney, DA, Gogas, H, de Bono, JS, Hamberg, KJ, Skov, T, and Mansi, JL (2002) A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. British Journal of Cancer, 86 (5). pp. 680-685. ISSN 0007-0920 (doi:10.1038/sj/bjc/6600162)

Evans, TR, and Keith, WN (2002) Telomerase and the senescence-like phenotype in cancer progression. Gastrointestinal Cancer Abstracts, 8 . pp. 2-5.

Keith, W.N., Bilsland, A., Evans, T.R.J., and Glasspool, R.M. (2002) Telomerase-Directed Molecular Therapeutics. Expert Reviews in Molecular Medicine (4). pp. 1-25. ISSN 1462-3994 (doi:10.1017/S1462399402004507)

Vasey, P.A., and Evans, T.R.J. (2002) Principles of chemotherapy and drug development. In: Price, P. and Sikora, K. (eds.) Treatment of Cancer. Arnold, London, UK, pp. 103-129. ISBN 9780340759646

2001

Mackay, HJ et al. (2001) A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Annals of Oncology, 12 (10). pp. 1407-1410. ISSN 0923-7534 (doi:10.1023/A:1012552823543)

Evans, TR (2001) Vaccine therapy for cancer - fact or fiction? Proceedings of the Royal College of Physicians of Edinburgh, 31 . pp. 9-16.

Keith, W.N., Evans, T.R.J., and Glasspool, R.M. (2001) Telomerase and cancer: time to move from a promising target to a clinical reality. Journal of Pathology, 195 (4). pp. 404-414. ISSN 0022-3417 (doi:10.1002/path.1001)

Plumb, J.A., Bilsland, A., Kakani, R., Zhao, J.Q., Glasspool, R.M., Knox, R.J., Evans, T.R.J., and Keith, W.N. (2001) Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene, 20 (53). pp. 7797-7803. ISSN 0950-9232